{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T06:33:53Z","timestamp":1709102033123},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Med."],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11684-012-0202-x","type":"journal-article","created":{"date-parts":[[2012,6,3]],"date-time":"2012-06-03T11:54:58Z","timestamp":1338724498000},"page":"204-211","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era"],"prefix":"10.1007","volume":"6","author":[{"given":"Haiyan","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,3]]},"reference":[{"issue":"15","key":"202_CR1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","volume":"319","author":"R. Kurzrock","year":"1988","unstructured":"Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319(15): 990\u2013998","journal-title":"N Engl J Med"},{"issue":"7","key":"202_CR2","first-page":"1217","volume":"10","author":"J.V. Melo","year":"1996","unstructured":"Melo JV, Yan XH, Diamond J, Lin F, Cross NC, Goldman JM. Reverse transcription\/polymerase chain reaction (RT\/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. Leukemia 1996; 10(7): 1217\u20131221","journal-title":"Leukemia"},{"issue":"4944","key":"202_CR3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"G.Q. Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 1990; 247(4944): 824\u2013830","journal-title":"Science"},{"issue":"18","key":"202_CR4","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","volume":"84","author":"J. McLaughlin","year":"1987","unstructured":"McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR\/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987; 84(18): 6558\u20136562","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"202_CR5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","volume":"108","author":"L. Roy","year":"2006","unstructured":"Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O\u2019Brien S, So C, Massimini G, Guilhot F. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108(5): 1478\u20131484","journal-title":"Blood"},{"issue":"23","key":"202_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"B.J. Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23): 2408\u20132417","journal-title":"N Engl J Med"},{"issue":"6","key":"202_CR7","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M. Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99(6): 1928\u20131937","journal-title":"Blood"},{"issue":"10","key":"202_CR8","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"C.L. Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O\u2019Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530\u20133539","journal-title":"Blood"},{"issue":"7","key":"202_CR9","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"J.W. Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100(7): 2292\u20132302","journal-title":"Blood"},{"issue":"1","key":"202_CR10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","volume":"47","author":"A. Trotti","year":"2000","unstructured":"Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W. Common toxicity criteria: version 2.0, an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47(1): 13\u201347","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"202_CR11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1532\/IJH97.06157","volume":"85","author":"E. Matsuo","year":"2007","unstructured":"Matsuo E, Miyazaki Y, Tsutsumi C, Inoue Y, Yamasaki R, Hata T, Fukushima T, Tsushima H, Imanishi D, Imaizumi Y, Iwanaga M, Sakai M, Ando K, Sawayama Y, Ogawa D, Kawaguchi Y, Nagai K, Tsukasaki K, Ikeda S, Moriuchi Y, Yoshida S, Honda M, Taguchi J, Onimaru Y, Tsuchiya T, Tawara M, Atogami S, Yamamura M, Soda H, Yoshida Y, Matsuo Y, Nonaka H, Joh T, Takasaki Y, Kawasaki C, Momita S, Jinnai I, Kuriyama K, Tomonaga M. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan. Int J Hematol 2007; 85(2): 132\u2013139","journal-title":"Int J Hematol"},{"issue":"6","key":"202_CR12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M. Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108(6): 1809\u20131820","journal-title":"Blood"},{"issue":"12","key":"202_CR13","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D. Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JF. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112(12): 4437\u20134444","journal-title":"Blood"},{"issue":"2","key":"202_CR14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","volume":"103","author":"M.E. O\u2019Dwyer","year":"2004","unstructured":"O\u2019Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, Mori M, Druker BJ. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004; 103(2): 451\u2013455","journal-title":"Blood"},{"issue":"26","key":"202_CR15","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A. Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, M\u00fcller MC, Hanfstein B, Haferlach C, G\u00f6hring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118(26): 6760\u20136768","journal-title":"Blood"},{"issue":"2","key":"202_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"N.P. Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2(2): 117\u2013125","journal-title":"Cancer Cell"},{"issue":"5531","key":"202_CR17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"M.E. Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293(5531): 876\u2013880","journal-title":"Science"},{"issue":"6","key":"202_CR18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","volume":"20","author":"F.E. Nicolini","year":"2006","unstructured":"Nicolini FE, Corm S, L\u00ea QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P, Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(\u03d5)-LMC GROUP). Leukemia 2006; 20(6): 1061\u20131066","journal-title":"Leukemia"},{"issue":"1","key":"202_CR19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S. Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102(1): 276\u2013283","journal-title":"Blood"},{"issue":"9","key":"202_CR20","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S. Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99(9): 3472\u20133475","journal-title":"Blood"},{"issue":"12","key":"202_CR21","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J. Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O\u2019Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110(12): 4005\u20134011","journal-title":"Blood"}],"container-title":["Frontiers of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-012-0202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11684-012-0202-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-012-0202-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:44:48Z","timestamp":1559421888000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11684-012-0202-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1007\/s11684-012-0202-x","relation":{},"ISSN":["2095-0217","2095-0225"],"issn-type":[{"value":"2095-0217","type":"print"},{"value":"2095-0225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}